Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Sanofi-Aventis Canada and Intelliject sign license agreement

Sanofi-aventis Canada has announced a licensing agreement with Intelliject, Inc. for a novel epinephrine auto injector for the emergency treatment of allergic reactions (anaphylaxis) in North America (U.S and Canada).

1 Dec 2009

Women less likely than men to receive major funds for scientific research, says study

Women were less likely than men to receive major funding for scientific research, according to a study from the University of Michigan Health System. The study also found that only a quarter of all researchers, both men and women, who received a major early career award went on to get further federal funding within five years.

1 Dec 2009

Researchers devise a way to deliver right therapy directly to tumors using aptamers

Finding and treating a tumor without disturbing normal tissue presents challenges - sometimes the most effective therapies can be invasive and harsh.

1 Dec 2009

European Patent Office grants patent EP1392642 for 4SC AG's lead auto-immune compound

4SC AG, a drug discovery and development company, today announced that the European Patent Office has granted patent EP1392642, which covers its lead auto-immune compound 4SC-101.

1 Dec 2009

University of Navarra Hospital launches clinical trials to assess the efficacy of immunotherapy treatment

The University of Navarra Hospital has launched a series of clinical trials in order to assess the efficacy of an immunotherapy treatment. This approach involves the application of personalised vaccines -produced from healthy and tumour cells from the patient him or herself- and designed to combat glioblastomas, one of the most aggressive and frequent malignant tumours.

1 Dec 2009

ChemGenex Pharmaceuticals to present updated clinical data from its clinical trials with Omapro

ChemGenex Pharmaceuticals Limited announced today that updated clinical data from several of its clinical trials with Omapro™ (omacetaxine mepesuccinate) will be presented at the upcoming 51st American Society of Hematology Annual Meeting in New Orleans, Louisiana.

1 Dec 2009

Clinical trials of personalised vaccines to fight glioblastomas

The University of Navarra Hospital has launched a series of clinical trials in order to assess the efficacy of an immunotherapy treatment. This approach involves the application of personalised vaccines —produced from healthy and tumour cells from the patient him or herself— and designed to combat glioblastomas, one of the most aggressive and frequent malignant tumours.

30 Nov 2009

Global CRO PRA International achieves Rave Accredited Plus status in the ASPire to Win program

Medidata Solutions, a leading global provider of hosted clinical development solutions, today announced that PRA International, a global clinical research organization (CRO), has achieved Rave Accredited Plus status in the ASPire to Win® program for CROs and other service providers.

30 Nov 2009

Bayer Healthcare Pharmaceuticals commences enrollment in florbetaben Phase III clinical trials

Today at the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), Bayer HealthCare Pharmaceuticals Inc. announced the enrollment of the first patient in an international Phase III clinical trial to evaluate the efficacy and safety of florbetaben (BAY 94-9172) PET imaging in the detection of beta-Amyloid plaques in the brain, which are a pathological hallmark of Alzheimer's disease.

30 Nov 2009

Xencor licenses its XmAb and Xtend technology platforms to Centocor Research & Development

Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation and biosuperior antibodies, announced today that it has licensed its XmAb® and Xtend™ technology platforms to Centocor Research & Development, Inc. for the optimization of Centocor’s antibody drug candidates.

30 Nov 2009

Kiadis Pharma commences enrollment in multinational ATIR study

Biopharmaceutical company Kiadis Pharma announces today that the first patients have been enrolled in its multinational registration clinical trial with ATIR(TM). The study is designed to show reduction in transplant related mortality (TRM) after one year following an allogeneic stem cell transplantation with a mismatched (haplo-identical) donor in blood cancer patients eligible for an allogeneic stem cell transplantation but without having a matched donor available.

30 Nov 2009

Spectrum Pharmaceuticals completes enrollment in apaziquone Phase 3 trial

Spectrum Pharmaceuticals today announced that one of the two Phase 3 pivotal clinical trials of apaziquone has achieved its enrollment target, having enrolled approximately 800 patients with non-invasive bladder cancer. The second Phase 3 clinical trial of apaziquone is expected to complete enrollment by the end of the year.

30 Nov 2009

Gentium announces financial results for the third quarter ended September 30, 2009

Gentium S.p.A. today reported financial results for the quarter ended September 30, 2009.

30 Nov 2009

Minerva Biotechnologies grants Clarient exclusive commercializing rights to its MUC1 diagnostic test

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that privately held, Waltham, MA-based Minerva Biotechnologies has granted it the exclusive right to develop and commercialize a test that identifies the MUC1* protein, a biomarker researchers believe may be implicated in the spread of many cancers, including breast cancer.

30 Nov 2009

Royal Philips Electronics demonstrates its portfolio of dose radiation managing products

Royal Philips Electronics today announced its response to an industry need by showing its portfolio of products designed to manage dose radiation at this year's 95th annual meeting of the Radiological Society of North America (RSNA) in Chicago.

From Philips Healthcare 30 Nov 2009

Siemens Healthcare to showcase latest medical imaging technologies at RSNA 2009

At the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), "Images, my way" will resonate throughout the Siemens Healthcare booth (#825) from November 29 to December 3 at McCormick Place (Booth #825, East Building/Lakeside Center, Hall D) in Chicago.

30 Nov 2009

Cell Therapeutics' platinum-based anti-tumor compounds demonstrate stronger anti-tumor potency

Cell Therapeutics, Inc. (CTI) announced today that its new class of platinum-based anti-tumor compounds, termed bis-platinates, demonstrated a stronger anti-tumor potency and activity compared to currently available platinum-based compounds as well as the ability to overcome cisplatin-resistance in cancer cell lines.

30 Nov 2009

Siemens Healthcare introduces syngo.via at RSNA annual meeting

Get ready for advanced visualization to become common practice in the clinical routine when Siemens introduces syngo.via at the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) from November 29 to December 3 at McCormick Place (Booth #825, East Building/Lakeside Center, Hall D) in Chicago.

30 Nov 2009

Siemens Healthcare to introduce high-end imaging systems for interventional oncological procedures at RSNA 2009

At the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) from November 29 to December 3 at McCormick Place in Chicago, Siemens Healthcare will introduce its comprehensive portfolio for imaging in interventional oncology at booth #825, East Building/Lakeside Center, Hall D.

30 Nov 2009

VIDA Diagnostics and Veran Medical to develop and market endobronchial lung navigation and biopsy system

VIDA Diagnostics, a leading developer of quantitative imaging software for the advanced analysis of pulmonary diseases, and Veran Medical Technologies, a leader in minimally invasive delivery of interventional oncology therapies, announced the companies have signed a definitive agreement covering joint development and distribution of an endobronchial lung navigation and biopsy system.

30 Nov 2009

Oncology News and Research

Further Reading

Sanofi-Aventis Canada and Intelliject sign license agreement

Women less likely than men to receive major funds for scientific research, says study

Researchers devise a way to deliver right therapy directly to tumors using aptamers

European Patent Office grants patent EP1392642 for 4SC AG's lead auto-immune compound

University of Navarra Hospital launches clinical trials to assess the efficacy of immunotherapy treatment

ChemGenex Pharmaceuticals to present updated clinical data from its clinical trials with Omapro

Clinical trials of personalised vaccines to fight glioblastomas

Global CRO PRA International achieves Rave Accredited Plus status in the ASPire to Win program

Bayer Healthcare Pharmaceuticals commences enrollment in florbetaben Phase III clinical trials

Xencor licenses its XmAb and Xtend technology platforms to Centocor Research & Development

Kiadis Pharma commences enrollment in multinational ATIR study

Spectrum Pharmaceuticals completes enrollment in apaziquone Phase 3 trial

Gentium announces financial results for the third quarter ended September 30, 2009

Minerva Biotechnologies grants Clarient exclusive commercializing rights to its MUC1 diagnostic test

Royal Philips Electronics demonstrates its portfolio of dose radiation managing products

Siemens Healthcare to showcase latest medical imaging technologies at RSNA 2009

Cell Therapeutics' platinum-based anti-tumor compounds demonstrate stronger anti-tumor potency

Siemens Healthcare introduces syngo.via at RSNA annual meeting

Siemens Healthcare to introduce high-end imaging systems for interventional oncological procedures at RSNA 2009

VIDA Diagnostics and Veran Medical to develop and market endobronchial lung navigation and biopsy system

Cancer Research eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News